Simple blood test may spot Alzheimer's early
NCT ID NCT01315639
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether measuring certain proteins in the blood (amyloid peptides) can help diagnose Alzheimer's disease or predict its progression. Over 1,000 older adults with mild cognitive impairment or Alzheimer's were followed for two years. Researchers compared blood levels of these proteins between those whose condition worsened and those who remained stable.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to help diagnose Alzheimer's disease earlier or predict how fast it will progress.
- What could go wrong
- This is an observational study, not a treatment trial. The blood test may not be accurate enough for routine use, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
1,067 people
The number who actually took part.
- Started
-
Sep 2010
- Finished
-
Mar 2018
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: MCI group : * ≥ 70 years * MCI diagnosis : New criteria (Petersen, PORTET\*) 1. cognitive complaint from the patient, family, or both, 2. report by the subject or reporter of a decline in cognitive or functional performance, relative to previous abilities, 3. cognitive disorders evidenced by clinical evaluation: impairment in memory or another cognitive domain, 4. cognitive impairment without any repercussion on daily life, even if the subject reports difficulties concerning complex daily activities, 5. no dementia * Having signed an informed consent form * Fluent in French AD group : * ≥ 45 years * AD diagnosis (DSM IV-TR et NINCDS-ADRDA) * Mild to moderate (MMSE \> 15) * Having signed an informed consent form * Caregiver/informant to provide information on patient Exclusion Criteria: * Normal cognitive function * Major depression (according to the DSMIV-TR or MINI or Geriatric depression Scale\> 20/30) * Genetic form of AD (genetic mutation known) * All other diseases that could interfere with cognitive assessment (Epilepsy, Parkinson's disease, schizophrenia, other dementia) * Major sensory deficits that could interfere with cognitive assessment (visual and auditory) * Diseases involving the short-term survival (advanced cancer, unstable heart disease, severe hepatic/respiratory/renal failure) * Contraindication for MRI, for lumbar puncture (i.e. anticoagulant agents) * Use of any experimental agent for the duration of the study * Participation to other biomedical research that could interfere with principal objective of the study * For MCI patient, use of IchE or memantine medication before inclusion * Less than 4 years of education * Illiteracy, is unable to count or to read * Pregnant women * Non health insurance affiliation * Private subjects of freedom by legal or administrative decision * Contraindication for MRI examination: * Claustrophobic subject * Carrying a cardiac pacemaker * Presence of any ferromagnetic metallic implants or foreign bodies (carrying an internal electrical/magnetic device, carrying a valvular prosthesis) * Carrying a ventricular valvular Exclusion criteria specific to the lumbar puncture: • Taking anticoagulant agents
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP, Hôpital Broca
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can group wellness classes improve life after brain injury or dementia?
- Can a personalized home program slow memory decline?
- Walking memory tests may reveal early Parkinson's clues
- Can tango rewire the brain? dance program tested for Parkinson's and dementia
- Can a home device slow dementia? pilot trial tests pulsed electromagnetic therapy
- Can a video chat keep dementia care true to Patients' wishes?